目的探讨拉米夫定的药理及在慢性乙型肝炎中的应用。方法选择2009年4月至2011年4月惠东县妇幼保健院收治慢性乙型肝炎患者20例,惠东县人民医院收治慢性乙型肝炎患者60例,分别采用安慰剂治疗和采用拉米夫定治疗,对其临床资料进行回顾性分析。结果观察组40例患者中,治疗12w后HBV-DNA转阴率为80%;ALT复常率为65%。对照组40例分别为10%、27.5%。两组比较差异均有统计学意义。两组均服用拉米夫定53周。HBV-DAN最终转阴率分别为77.5%、75%,ALT最终复常率为72.5%、70%。差异均无统计学意义(P>0.05)。结论慢性乙型肝炎患者采用拉米夫定治疗,可抑制HBV的复制,恢复ALT水平,有良好耐受性,不良反应少,值得临床推广应用。 Objective To investigate the pharmacology of lamivudine and its application in chronic hepatitis B. Methods From April 2009 to April 2011, 20 cases of chronic hepatitis B were treated in Huidong MCH hospital, 60 cases of chronic hepatitis B were treated in Huidong County People’s Hospital, and were treated with placebo and Lamiv Given treatment, its clinical data were retrospectively analyzed. Results Among the 40 patients in the observation group, the HBV-DNA negative rate was 80% after 12 weeks of treatment and the rate of ALT normalization was 65%. Control group 40 cases were 10%, 27.5%. The difference between the two groups was statistically significant. Both groups took lamivudine for 53 weeks. The final negative conversion rates of HBV-DNA were 77.5% and 75%, respectively. The final ALT recovery rate was 72.5% and 70% respectively. There was no significant difference (P> 0.05). Conclusion The treatment of lamivudine in patients with chronic hepatitis B can inhibit the replication of HBV, restore the level of ALT, have good tolerance and few adverse reactions, which is worthy of clinical application.